Posted by Michael Wonder on 19 Oct 2025
Enterome receives FDA fast track designation in follicular lymphoma for lead OncoMimics immunotherapy EO2463
16 October 2025 - Enterome announces today that the US FDA has granted fast track designation for follicular lymphoma in the low tumour burden “watch and wait” setting for its lead OncoMimics immunotherapy, EO2463.
EO2463 is an innovative, off the shelf OncoMimics active immunotherapy that combines four synthetic peptides.
